Reactivation of low avidity tumor-specific CD8 + T cells associates with immunotherapeutic efficacy of anti-PD-1.
Gessa SugiyartoDoreen LauSamuel Luke HillDavid Arcia-AnayaDenise S M BoulangerEileen E ParkesEdward JamesTim ElliottPublished in: Journal for immunotherapy of cancer (2023)
Targeting subdominant T cell responses with lower avidity against pMHC affinity neoepitopes showed potential for improving PD-1 immunotherapy. Future interventions may consider expanding low avidity populations via vaccination or adoptive transfer.